Beyond glycemic control: nephroprotective effects of glucagon-like peptide 1 receptor agonists


DOI: https://dx.doi.org/10.18565/nephrology.2021.3.84-91

M.S. Shamkhalova, I.A. Sklyanik, M.V. Shestakova

National Medical Research Center for Endocrinology, Moscow, Russia
Chronic kidney disease in patients with diabetes mellitus (DM) is the leading cause of end-stage renal failure (ESRD), which determines the high risk of cardiovascular disease and mortality. Advances in diabetes management do not reverse the risks of ESRD, but shift them in line with age and duration of illness. According to large studies of cardiovascular safety, modern hypoglycemic drugs – glucagon-like peptide 1 receptor agonists (GLP-1RAs), effectively control glycemia, components of the metabolic syndrome and significantly reduce the risk of a primary 3-component endpoint (MACE) and have an underestimated nephroprotective potential. The renal effects of GLP-1RAs are determined by the anti-inflammatory, antiapoptotic, antioxidant properties of this group of drugs.
Keywords: glucagon-like peptide 1 receptor agonists, diabetes mellitus, nephroprotection, chronic kidney disease
Read entire article

About the Autors

Minara S. Shamkhalova – Dr.Sci. (Med.), National Medical Research Center for Endocrinology, Moscow, Russia; e-mail: shamkhalova@mail.ru.
ORCID: https://orcid.org/0000-0002-3433-0142; eLibrary SPIN: 4942-5481
Igor A. Sklyanik – Researcher, National Medical Research Center for Endocrinology, Moscow, Russia; e-mail: sklyanik.igor@gmail.com.
ORCID: https://orcid.org/0000-0002-7768-4717; eLibrary SPIN: 7081-8077.
Marina V. Shestakova – Academician of the Russian Academy of Sciences, Dr. Sci. (Med.), Prof., National Medical Research Center for Endocrinology, Moscow, Russia;
e-mail: nephro@endocrincentr.ru. ORCID: https://orcid.org/0000-0002-5057-127X; eLibrary SPIN: 7584-7015


Similar Articles

Back to Content

Бионика Медиа